Quince Therapeutics shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced an $11 price target.
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics shares rose after Rodman & Renshaw initiated coverage with a Buy rating and set an $11 price target.
October 29, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quince Therapeutics shares increased following Rodman & Renshaw's initiation of coverage with a Buy rating and an $11 price target.
The initiation of coverage by Rodman & Renshaw with a Buy rating and a specific price target of $11 is a positive signal to investors, likely leading to increased buying interest and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100